
• Available as analytical standard and GMP grade, including Isotope-labeled compounds, Reference Standards, GMP Small Molecules.
• Widely used in leading research areas of biology, chemistry, medicine and pharmacology.
• High purity, superior quality, and stringent quality control.
• Biological activity validated by researchers worldwide.
• Comprehensive modifications: 2’-F, 2’-Ome, 2’-MOE, phosphorothioate (PS), locked nucleic acid (LNA), Cy3, and Cy5, and more.
• Strong synthesis capacity: flexible scales from milligrams to kilograms.
• 20+ GMP small molecules for ADC: (Payloads, Drug-Linker Conjugates and related intermediates).
• One-stop services: design and synthesis drug-linker conjugates, custom ADCs and more.
• Derived services: synthesis PAC, AOC, PDC, ApDC, FDC, RDC, ISAC, VDC, SMDC, etc.

Full-process drug development services covering compound library supply, screening services, lead compound optimization, and customized synthesis of compounds for preclinical and clinical studies.
Different libraries meet different research needs!

Novel structure with excellent diversity, each BMS scaffold containing 1 to 5 molecules, easy to synthesize via standard 1-2 step procedures.
Suitable for AI screening and virtual screening.

Suitable for new drug development.

by Structure Series
by Pathway Series
by Character Series

| Cat. No | Product Name | Number of Compounds |
|---|---|---|
| HY-L009 | Kinase Inhibitor Library | 3,400+ |
| HY-L021 | Natural Product Library | 5,000+ |
| HY-L022 | FDA-Approved Drug Library | 3,200+ |
| HY-L028 | CNS-Penetrant Compound Library | 1,000+ |
| HY-L030 | Human Endogenous Metabolite Compound Library | 1,000+ |
| HY-L036 | Covalent Screening Library | 1,500+ |
| HY-L041 | Macrocyclic Compound Library | 400+ |
| HY-L043 | Lipid Compound Library | 1,600+ |
| HY-L105 | Peptide Library | 2,000+ |
| HY-L151 | PROTAC Library | 400+ |

2. 2026 MCE calendar with every shipment, with no minimum order required.
3. For inquiries, please contact us at [email protected].
4. MCE reserves the right of final interpretation.

• Available as analytical standard and GMP grade, including Isotope-labeled compounds, Reference Standards, GMP Small Molecules.
• Widely used in leading research areas of biology, chemistry, medicine and pharmacology.
• High purity, superior quality, and stringent quality control.
• Biological activity validated by researchers worldwide.
• Comprehensive modifications: 2’-F, 2’-Ome, 2’-MOE, phosphorothioate (PS), locked nucleic acid (LNA), Cy3, and Cy5, and more.
• Strong synthesis capacity: flexible scales from milligrams to kilograms.
• 20+ GMP small molecules for ADC: (Payloads, Drug-Linker Conjugates and related intermediates).
• One-stop services: design and synthesis drug-linker conjugates, custom ADCs and more.
• Derived services: synthesis PAC, AOC, PDC, ApDC, FDC, RDC, ISAC, VDC, SMDC, etc.

Full-process drug development services covering compound library supply, screening services, lead compound optimization, and customized synthesis of compounds for preclinical and clinical studies.
Different libraries meet different research needs!

Novel structure with excellent diversity, each BMS scaffold containing 1 to 5 molecules, easy to synthesize via standard 1-2 step procedures.
Suitable for AI screening and virtual screening.

Suitable for new drug development.

by Structure Series
by Pathway Series
by Character Series

| Cat. No | Product Name | Number of Compounds |
|---|---|---|
| HY-L009 | Kinase Inhibitor Library | 3,400+ |
| HY-L021 | Natural Product Library | 5,000+ |
| HY-L022 | FDA-Approved Drug Library | 3,200+ |
| HY-L028 | CNS-Penetrant Compound Library | 1,000+ |
| HY-L030 | Human Endogenous Metabolite Compound Library | 1,000+ |
| HY-L036 | Covalent Screening Library | 1,500+ |
| HY-L041 | Macrocyclic Compound Library | 400+ |
| HY-L043 | Lipid Compound Library | 1,600+ |
| HY-L105 | Peptide Library | 2,000+ |
| HY-L151 | PROTAC Library | 400+ |

2. MCE reserves the right of final interpretation.
2. For inquiries, please contact us at [email protected].
3. MCE reserves the right of final interpretation.

